Treatment of uncomplicated falciparum malaria, when artemisinin-based combinations cannot be used
Completion treatment following parenteral therapy with quinine for severefalciparum malaria, when artemisinin-based combinations cannot be used
Forms and strengths
300 mg quinine sulfate tablet
Dosage and duration
Dosage is expressedin terms of salt. Exceptfor quinine bisulfate, the dosage is the same for all quininesalts (sulfate, hydrochloride, dihydrochloride):
Child and adult < 50 kg: 10 mg/kg 3 times daily at 8-hour intervals for 7 days
Adult ≥ 50 kg: 600 mg 3 times daily at 8-hour intervals for 7 days
Age
Weight
300 mg tablet
5 months to < 2 years
7to < 12 kg
¼ tab x 3
2 to < 8 years
12to < 25 kg
½ tab x 3
8 to < 11 years
25to < 35 kg
1 tab x 3
11 to < 14 years
35to < 50 kg
1½ tab x 3
≥ 14 years
≥50 kg
2 tab x 3
Contra-indications, adverse effects, precautions
May cause: headache, skin rash; visual, auditory and gastrointestinal disturbances. Do not exceed indicated doses: risk of toxicity in the event of overdose.
Avoid combination with drugs that prolong QT interval: amiodarone, other
antimalarials, antipsychotics, fluconazole, fluoroquinolones, hydroxyzine, macrolides, ondansetron, etc.
If the patient vomits within 30 minutes after administration, re-administer the full dose. If the patient vomits between 30 minutes and 1 hour after administration, re-administer half of the dose.
Pregnancy: no contra-indication; it is recommended to administer quinine in combination with clindamycin if possible.
Breast-feeding: no contra-indication
Remarks
10 mg of quinine sulfate or hydrochloride or dihydrochloride = 8 mg of quinine base; 14 mg of quinine bisulfate= 8 mg of quinine base.